Dicerna Pharmaceuticals, Inc. DRNA
Set alert
38.22 +38.22 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 2.98B
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -19.11
- Beta
- 0.79
- Short ratio
- 0.84
- Inst. own
- 88.54%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2021
- 50-d avg
- 31.45
- 200-d avg
- 28.97
- 1y target
- 38.25
Analyst view
Consensus: hold
Hold
Price target (mean) 38.25
Ratings (0m) 5 3 buy · 2 hold · 0 sell
- Strong buy1
- Buy2
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 8
- 2 months ago 8
- 3 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.54 | -0.99 – -0.04 | -0.49 | -10.2% | 41.27M | +0.8% | 8 |
| Next quarter | -0.67 | -0.92 – -0.27 | -0.39 | -71.8% | 34.01M | -26.5% | 6 |
| Current year | -1.68 | -2.13 – -1.17 | -1.52 | -10.5% | 192.92M | +17.4% | 9 |
| Next year | -2.00 | -3.88 – -0.41 | -1.68 | -19.0% | 191.11M | -0.9% | 9 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 9, 2021 | Chardan Capital | Downgrade | Buy | Neutral |
| Nov 19, 2021 | RBC Capital | Downgrade | Outperform | Sector Perform |
| Nov 18, 2021 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Aug 11, 2021 | Goldman Sachs | Downgrade | Buy | Neutral |
| Aug 10, 2021 | Chardan Capital | Maintained | — | Buy |
| Aug 10, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Aug 9, 2021 | Citigroup | Downgrade | Buy | Neutral |
| Aug 6, 2021 | RBC Capital | Maintained | — | Outperform |
| Aug 6, 2021 | Goldman Sachs | Maintained | — | Buy |
| Aug 6, 2021 | SVB Leerink | Maintained | — | Outperform |
| Aug 6, 2021 | Cowen & Co. | Downgrade | Outperform | Market Perform |
| Aug 6, 2021 | Truist Securities | Downgrade | Buy | Hold |
| Aug 6, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Jun 23, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Apr 16, 2021 | Goldman Sachs | Initiated | — | Buy |
| Apr 8, 2021 | SVB Leerink | Maintained | — | Outperform |
| Mar 2, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Mar 2, 2021 | Chardan Capital | Maintained | — | Buy |
| Nov 25, 2020 | SVB Leerink | Maintained | — | Outperform |
| Aug 7, 2020 | SVB Leerink | Maintained | — | Outperform |
| Aug 7, 2020 | HC Wainwright & Co. | Maintained | — | Buy |
| May 13, 2020 | RBC Capital | Initiated | — | Outperform |
| May 11, 2020 | SunTrust Robinson Humphrey | Maintained | — | Buy |
| Apr 7, 2020 | H.C. Wainwright | Maintained | — | Buy |
| Apr 7, 2020 | SVB Leerink | Maintained | — | Outperform |
| Mar 19, 2020 | Berenberg | Initiated | — | Buy |
| Feb 28, 2020 | Stifel Nicolaus | Maintained | — | Buy |
| Jan 9, 2020 | B. Riley FBR | Maintained | — | Buy |
| Dec 18, 2019 | Citigroup | Maintained | — | Buy |
| Nov 25, 2019 | Baird | Maintained | — | Outperform |